JCI Insight (Dec 2021)

T cell–derived tumor necrosis factor induces cytotoxicity by activating RIPK1-dependent target cell death

  • Nicholas Chun,
  • Rosalind L. Ang,
  • Mark Chan,
  • Robert L. Fairchild,
  • William M. Baldwin III,
  • Julian K. Horwitz,
  • Jesse D. Gelles,
  • Jerry Edward Chipuk,
  • Michelle A. Kelliher,
  • Vasile I. Pavlov,
  • Yansui Li,
  • Dirk Homann,
  • Peter S. Heeger,
  • Adrian T. Ting

Journal volume & issue
Vol. 6, no. 24

Abstract

Read online

TNF ligation of TNF receptor 1 (TNFR1) promotes either inflammation and cell survival by (a) inhibiting RIPK1’s death-signaling function and activating NF-κB or (b) causing RIPK1 to associate with the death-inducing signaling complex to initiate apoptosis or necroptosis. The cellular source of TNF that results in RIPK1-dependent cell death remains unclear. To address this, we employed in vitro systems and murine models of T cell–dependent transplant or tumor rejection in which target cell susceptibility to RIPK1-dependent cell death could be genetically altered. We show that TNF released by T cells is necessary and sufficient to activate RIPK1-dependent cell death in target cells and thereby mediate target cell cytolysis independently of T cell frequency. Activation of the RIPK1-dependent cell death program in target cells by T cell–derived TNF accelerates murine cardiac allograft rejection and synergizes with anti-PD1 administration to destroy checkpoint blockade–resistant murine melanoma. Together, the findings uncover a distinct immunological role for TNF released by cytotoxic effector T cells following cognate interactions with their antigenic targets. Manipulating T cell TNF and/or target cell susceptibility to RIPK1-dependent cell death can be exploited to either mitigate or augment T cell–dependent destruction of allografts and malignancies to improve outcomes.

Keywords